E-Submission
Yeungnam University College of MedicineIndexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
Search
- Page Path
- HOME > Search
Review article
- Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
- In Cheol Yoon, Jong Ryeol Eun
- Yeungnam Univ J Med. 2019;36(2):67-77. Published online April 11, 2019
- DOI: https://doi.org/10.12701/yujm.2019.00171
- 9,359 View
- 200 Download
- 5 Crossref
-
Abstract
PDF - The paradigm of chronic liver diseases has been shifting. Although hepatitis B and C viral infections are still the main causes of liver cirrhosis and hepatocellular carcinoma (HCC), the introduction of effective antiviral drugs may control or cure them in the near future. In contrast, the burden of nonalcoholic fatty liver disease (NAFLD) has been increasing for decades, and 25 to 30% of the general population in Korea is estimated to have NAFLD. Over 10% of NAFLD patients may have nonalcoholic steatohepatitis (NASH), a severe form of NAFLD. NASH can progress to cirrhosis and HCC. NASH is currently the second leading cause to be placed on the liver transplantation list in the United States. NAFLD is associated with obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. The pathophysiology is complex and associated with lipotoxicity, inflammatory cytokines, apoptosis, and insulin resistance. The only proven effective treatment is weight reduction by diet and exercise. However, this may not be effective for advanced fibrosis or cirrhosis. Therefore, effective drugs are urgently needed for treating these conditions. Unfortunately, no drugs have been approved for the treatment of NASH. Many pharmaceutical companies are trying to develop new drugs for the treatment of NASH. Some of them are in phase 2 or 3 clinical trials. Here, pharmacologic therapies in clinical trials, as well as the basic principles of drug therapy, will be reviewed, focusing on pathophysiology.
-
Citations
Citations to this article as recorded by
- Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
Tharani Senavirathna, Armaghan Shafaei, Ricky Lareu, Lois Balmer
Antioxidants.2024; 13(4): 485. CrossRef - Effect of Lactobacillus rhamnosus hsryfm 1301 Fermented Milk on Lipid Metabolism Disorders in High-Fat-Diet Rats
Hengxian Qu, Lina Zong, Jian Sang, Yunchao Wa, Dawei Chen, Yujun Huang, Xia Chen, Ruixia Gu
Nutrients.2022; 14(22): 4850. CrossRef - Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease
Yuanqiang Ma, Gyurim Lee, Su-Young Heo, Yoon-Seok Roh
Antioxidants.2021; 11(1): 91. CrossRef - Elevated 1-h post-load plasma glucose levels in normal glucose tolerance children with obesity is associated with early carotid atherosclerosis
Suna Kılınç, Tuna Demirbaş, Enver Atay, Ömer Ceran, Zeynep Atay
Obesity Research & Clinical Practice.2020; 14(2): 136. CrossRef - Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská
Frontiers in Endocrinology.2020;[Epub] CrossRef
- Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
First
Prev
